# A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT04017130** · PHASE1 · TERMINATED · sponsor: **Molecular Templates, Inc.** · enrollment: 14 (actual)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** MT-0169

## Key facts

- **NCT ID:** NCT04017130
- **Lead sponsor:** Molecular Templates, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-05
- **Primary completion:** 2023-12-13
- **Final completion:** 2023-12-13
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Sparse/no patient enrollment
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04017130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04017130, "A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04017130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*